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Abstract We exploit the recent availability of a com-
munity reconstruction of the human metabolic network
(‘Recon2’) to study how close in structural terms are
marketed drugs to the nearest known metabolite(s) that
Recon2 contains. While other encodings using different
kinds of chemical fingerprints give greater differences, we
find using the 166 Public MDL Molecular Access (MAC-
CS) keys that 90 % of marketed drugs have a Tanimoto
similarity of more than 0.5 to the (structurally) ‘nearest’
human metabolite. This suggests a ‘rule of 0.5’ mnemonic
for assessing the metabolite-like properties that character-
ise successful, marketed drugs. Multiobjective clustering
leads to a similar conclusion, while artificial (synthetic)
structures are seen to be less human-metabolite-like. This
‘rule of 0.5’ may have considerable predictive value in
chemical biology and drug discovery, and may represent a
powerful filter for decision making processes.
Keywords Genome-wide metabolic reconstruction 
Recon 2  Cheminformatics  KNIME  Metabolite-
likeness  Drug-likeness
1 Introduction
The declining productivity of the drug discovery process is
well known (e.g. Empfield and Leeson 2010; Hay et al.
2014; Kell 2013; Kola 2008; Kola and Landis 2004; Rafols
et al. 2014; van der Greef and McBurney 2005). Thus,
many groups have sought to assess in silico those structural
or biophysical properties of successful drugs that might be
used as filters to enrich the contents of drug discovery
libraries with molecules that share those properties. This
has therefore led to concepts such as ‘‘drug-likeness’’ (e.g.
Empfield and Leeson 2010; Hay et al. 2014; Kell 2013;
Kola 2008; Kola and Landis 2004; van der Greef and
McBurney 2005), ‘‘lead-likeness’’ (Gozalbes and Pineda-
Lucena 2011; Holdgate 2007; Oprea et al. 2007, 2001;
Wunberg et al. 2006), and ‘‘ligand efficiency’’ (Hopkins
et al. 2014) by which the potentially desirable properties of
such molecules have been assessed.
We recognise that any molecule bioactive in human
cells (whether as a drug or for purposes of chemical
genomics) must cross at least one membrane, that nutrients
necessarily do so, that natural products remain a major
source of successful (marketed) pharmaceutical drugs
(Gozalbes and Pineda-Lucena 2011; Holdgate 2007; Oprea
et al. 2007, 2001; van Deursen et al. 2011; Wunberg et al.
2006), and that successful drugs require or at least use
membrane transporters (Dobson et al. 2009; Dobson and
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Kell 2008; Giacomini and Huang 2013; Giacomini et al.
2010; Kell 2013; Kell and Dobson 2009; Kell et al. 2013,
2011; Kell and Goodacre 2014; Lanthaler et al. 2011) that
normally are used for the transport of intermediary
metabolites (Herrga˚rd et al. 2008; Swainston et al. 2013;
Thiele et al. 2013). Given the natural role for these trans-
porters as transporters of intermediary metabolites, we and
others have thus suggested (hypothesised) that successful
drugs are in fact much more like metabolites (we use this
term to mean the natural intermediary metabolites of
human metabolism, and do not consider metabolites of the
drugs) than are the typical structures found in drug dis-
covery libraries (e.g. Chen et al. 2012; Dobson et al. 2009;
Feher and Schmidt 2003; Gupta and Aires-de-Sousa 2007;
Hamdalla et al. 2013; Karakoc et al. 2006; Khanna and
Ranganathan 2009, 2011; Peironcely et al. 2011; Walters
2012; Zhang et al. 2011), and following the principle of
molecular similarity (e.g. Bender and Glen 2004; Eckert
and Bajorath 2007; Gasteiger 2003; Maldonado et al. 2006;
Oprea 2004; Sheridan et al. 2004) that ‘‘metabolite-like-
ness’’ is therefore a useful criterion for the design of suc-
cessful drugs (Dobson et al. 2009). At one level, this may
not be seen as surprising given the fact that pharmaceutical
drugs typically bind to proteins at sites to which endoge-
nous metabolites normally bind, but the recognition of the
importance of metabolite-likeness in drug discovery and
chemical genomics remains less than complete.
While a variety of metabolite (pathway) databases exist
(Ooi et al. 2010) [e.g. ChEBI (de Matos et al. 2012; De-
gtyarenko et al. 2009; Hastings et al. 2013), HMDB
(Wishart et al. 2013), KEGG (Kanehisa et al. 2012, 2014),
MetaCyc (Altman et al. 2013; Caspi et al. 2014; Karp and
Caspi 2011) and MetaboLights (Haug et al. 2013)], the
recent availability of a highly curated consensus map
(Recon2) of the human metabolic network (and thus of
intermediary metabolites) (Swainston et al. 2013; Thiele
et al. 2013) now provides the most suitable starting point
for the comparison of drugs that have been approved/
marketed [available from DrugBank (Knox et al. 2011;
Law et al. 2014)] and metabolites that are known to be part
of the human metabolic network. We choose this latter
over say HMDB since the measurable presence of a mol-
ecule in a human sample (e.g. Dunn et al. 2014) does not
exclude that it has a nutritional, xenobiotic or gut microbial
origin, and HMDB does contain many ‘metabolites’ that
are not in fact produced via pathways containing proteins
encoded by the human genome. Indeed Peironcely et al.
(2011) noted, for instance, that the ‘metabolite’ debrisoq-
uine was indeed classified in their scheme as a non-
metabolite (and it is indeed a marketed drug).
Thus the primary purpose of this work (in contrast to our
earlier work (Dobson et al. 2009) that included multiple
metabolite databases that were not constrained as here), is
to use the availability of Recon2 to assess precisely how
‘metabolite-like’ known drugs are, partly as an aid to
developing metrics for determining whether drugs are
likely to be substrates for relevant transporters and thus
whether they are likely to be bioactive. The availability of
Recon2 also allows us to reason sensibly about the nature
and extent of metabolite space and how it differs from the
kinds of molecules typically found in drug discovery
libraries.
2 Methods
2.1 Construction of datasets
The list of FDA-approved small molecule drugs was
downloaded from DrugBank 3.0 (http://www.drugbank.ca/
downloads) in November 2013 as an SDF file and consists
of 1491 molecules. This is significantly smaller than the
fuller list (7330 ‘drugs’ via Drugbank and KEGGDrug)
used previously (Dobson et al. 2009). The list of interme-
diary metabolites was extracted from the latest version of
the Recon2 human metabolic network (Thiele et al. 2013).
A further manual curation removed from the ‘drugs’ list
(i) ‘drugs’ (mainly nutritional supplements) that are also
intermediary metabolites produced by enzymes encoded by
the genome and thus part of Recon 2 (though adrenaline
was treated as a drug), and (ii) those ‘metabolites’ listed in
Recon2 that are xenobiotic in nature or simply metals or
salts. However, vitamins and essential amino acids and
fatty acids, while not encoded by the human genome, were
retained as ‘metabolites’ as they are both necessary for
human metabolism and form part of the formal human
metabolic network. The resultant data are in Supplemen-
tary information S3, and consist of 1113 ‘metabolites’ [cf.
5333 ‘metabolites’ previously (Dobson et al. 2009)] and
1381 ‘drugs’. In addition, data on antimalarial compounds
were downloaded from the databases at the EBI (https://
www.ebi.ac.uk/chemblntd).
2.2 Software
For the cheminformatics analyses we used the KoNstanz
Information MinEr (KNIME, www.knime.org) (Beisken
et al. 2013; Berthold et al. 2007; Mazanetz et al. 2012;
Meinl et al. 2012; Sto¨ter et al. 2013; Warr 2012). KNIME
is a workflow environment somewhat similar to Taverna
[with which we have previous experience in systems
biology analyses (Li et al. 2008a, b)], but which is slightly
more focussed on cheminformatics. The workflows we
used here included nodes that made use of libA-
nnotationSBML (Swainston and Mendes 2009), the
Chemistry Development Kit (Beisken et al. 2013;
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Steinbeck et al. 2003) and the RDKit (Riniker and Lan-
drum 2013a; b; Saubern et al. 2011) (www.rdkit.org/). We
also used the software MOCK (Handl and Knowles 2007)
for multiobjective clustering.
3 Results
3.1 Comparison of Tanimoto distances between drugs
and natural metabolites
Our first task was to assess the average chemical (structure)
distances between molecules according to a suitable met-
ric. Many molecular descriptors exist for encoding mole-
cules in a manner that allows this (e.g. Bender 2010; Duan
et al. 2010; Koutsoukas et al. 2013; Sastry et al. 2010;
Sheridan and Kearsley 2002; Todeschini and Consonni
2000; Wang and Bajorath 2010), most commonly referred
to as fingerprints (e.g. Faulon and Bender 2010; Flower
1998) and sometimes with rather different properties and
outcomes when matched against structures or biological
activities (e.g. Dhanda et al. 2013; Medina-Franco and
Maggiora 2014). Thus, and while some experience shows
that they are not greatly different from each other when
simply comparing chemical or structural similarity (Dob-
son et al. 2009; Riniker and Landrum 2013a), which is the
focus of the present paper, we looked at a number of
methods for producing molecular fingerprints. Probably
most common are fingerprints derived from structural keys
such as the 166 Public MDL (Molecular ACCess System)
MACCS keys (Durant et al. 2002) based on a predefined
dictionary of 166 substructures [that contain most of the
important features of a larger 960-key set (McGregor and
Pallai 1997)] and hashed to give 1,024 bits.
Given the molecular fingerprint method chosen, there is
a more general acceptance of the metrics for the similarity
of molecules whose (sub)structures are so encoded;
although it has a size-dependence (that does not matter for
this analysis), the Tanimoto distance, that effectively
encodes the numbers of matching and non-matching sub-
structures, is both easy to calculate and pre-eminent
(Maggiora et al. 2014; Willett 2006).
We recognise that some 20 % of recent new chemical
entities are prodrugs (15 % in the top 100 drugs) (Huttunen
et al. 2011), and that some of these are converted non-
enzymically to the active substances; however, these nor-
mally do not differ greatly in structural terms from the
active substance in the marketed entities, so for conve-
nience we shall use the latter. In contrast to Peironcely
et al. (2011), who used supervised learning methods such
as random forests [which are very powerful (Knight et al.
2009)] to predict whether a substance was or was not a
metabolite, we are here interested only in the structural
similarities between candidate molecules and Recon2
metabolites, and we confine ourselves strictly to unsuper-
vised methods of analysis.
We checked a variety of implementations of the
MACCS fingerprints (specifically those used in Open
Babel, CDK and RDKit) and found very little difference
between them, and for what is presented here we used those
in the RDKit implementation. We therefore compared all
metabolites against all metabolites (Fig. 1a), all drugs
against all drugs (Fig. 1b), and all drugs against all
metabolites (Fig. 1c). The metabolite-metabolite similari-
ties (Fig. 1a) reveal multiple clusters, including one that is
made up of CoA derivatives (full details in Figure S1),
while the clusters of drug-drug similarities Fig. 1b are
rather more heterogeneous (the trees are much ‘bushier’).
From Fig. 1c, the drug-metabolite similarities, there are
some interesting clusters, e.g. the block of red and yellow
towards the upper left represented sterols and steroids,
while the larger swathe of red and yellow towards the
bottom represents mainly CoA derivatives. All the data are
given in an addressable form as Excel spreadsheets in
Supplementary Information S1–S3.
A number of different fingerprints were used to deter-
mine if the extent of closeness of a drug to its nearest
metabolite depended greatly on the fingerprint used. The
various fingerprints used (http://www.rdkit.org/RDKit_
Docs.current.pdf) were provided in the RDKit module
(Riniker and Landrum 2013a) (https://code.google.com/p/
rdkit/wiki/FingerprintsInTheRDKit) of KNIME (http://
tech.knime.org/community/rdkit), and as stated in (Riniker
and Landrum 2013b) were atom pairs (AP), feature-based
circular fingerprint with radius 2 as bit vector (FeatMor-
gan2), and a circular fingerprint with radius 2 as bit vector
(Morgan2). Morgan2 is the RDKit implementation of the
familiar ECFP4, and FeatMorgan2 is equivalent to FCFP4
(Landrum et al. 2011). The features used by the RDKit for
FeatMorgan2 consist of various donors, acceptors, aro-
matic atoms, halogens, basic and acidic atoms. We also
used a representation (referred to in KNIME and here as
‘RDKit’) that is said to be a ‘Daylightlike’ topological
fingerprint based on hashing molecular subgraphs. Most
recently, RDKit has added some extra fingerprints, and for
completeness we included these too. Thus, ‘layered’ is an
experimental substructure fingerprint using hashed molec-
ular subgraphs, while ‘torsion’ is said to be the bit vector
topological-torsion fingerprint for a molecule. As indicated
above, all of the data are tabulated in Fig S3.
Considering first just the Tanimoto similarity (TS) val-
ues using MACCS fingerprints and the 1,024 bitstring
encoding, 90 % of marketed drugs have a ‘nearest
metabolite Tanimoto similarity’ (NMTS, i.e. the TS to the
nearest metabolite) of more than 0.5, 98.5 % over 0.4 and
99 % over 0.34, all highly significant values (Baldi and
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Fig. 1 Heat maps of the overall
similarities between a Recon2
metabolites, b drugs and c each
other. In the latter plot, the
drugs lie on the X-axis and the
metabolites on the Y-axis.
Chemical structures were
encoded using the MACCS
encoding and Tanimoto
distances calculated as
described in Methods. The heat
map representation (Eisen et al.
1998) encodes the numbers as a
colour; in the present version,
for ease of observation, we use
ten discrete colours for the ten
decades of Tanimoto similarity,
with the colours chosen
following the recommendations
of Brewer et al. (1997) (see also
http://www.colorbrewer2.org/).
Also shown are hierarchical
clusterings of the rows and col-
umns (Eisen et al. 1998) using
complete linkage and the default
settings in the hclust function in
R (Color figure online)
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Nasr 2010). The first of those percentages compares with
just 12 % when we did not use the ‘genuine’ human
metabolites of Recon2 (Dobson et al. 2009) (note that there
we used the nearest Tanimoto distance (=1 - TS)). Pro-
vided the molecule is not excessively halogenated, its
NMTS is over 0.5 (e.g. 0.54 for Chlorzoxazone, 0.55
chlormerodrin, 0.6 diclofenac, 0.65 chlorphenesin and so
on). This ‘rule’, by which the very great majority (90 % of)
drugs are within a Tanimoto distance of 0.5 in MACCS
fingerprint space, may be viewed in the context of the well-
known ‘rule of 5’ (Lipinski et al. 1997) (Ro5) mnemonic
for predicting drug lead quality. However, the cumulative
plots of the NMTS for each drug using different finger-
prints (Fig. 2a) do differ quite significantly depending on
which fingerprint is used, and clearly the well-established
MACCS fingerprints lead to a substantially greater degree
of ‘metabolite-likeness’ than do almost all the other en-
codings (we do not pursue this here). Figure 2 also permits
one to read off other metrics such as to note that more than
50 % of drugs have a TS greater than 0.6 to a metabolite
for both MACCS and RDKit encodings.
Another indication of the rather different nature of the
fingerprints comes from an analysis (Table 1) of the nature,
and frequency of occurrence, of the nearest metabolite,
where each fingerprint encoding has its own predilections
for particular classes of metabolite, reflected also in the
overall number of metabolites that are closest to at least one
drug. These represent about one quarter of all drugs (or
metabolites), an indication of the significant heterogeneity
(Hopkins et al. 2014; Paolini et al. 2006) of drug space.
RDKit has a slightly unusual predilection for cob(1)alamin
and for protoheme, returned as the closest hits on 650 and
73 occasions, respectively (although removing these has
negligible effects on the shape of the plot in Fig. 2a, indi-
cating that this lower degree of metabolite-likeness, which
is a continuous function, is inherent to the encoding).
Scatter plots indicating correlations of ‘nearest metabolites’
with the different encodings are given in Fig. 2b, again
illustrating the substantial differences found using the dif-
ferent encodings. Thus we would stress not only that sim-
ilarity measures differ significantly for the different
encodings, but that in functional terms the well-known
existence of activity cliffs (e.g. Maggiora et al. 2014) means
that quite small differences in molecular similarity may be
highly significant with regard to pharmacological effects. In
contrast to studies of related molecules that look at this (e.g.
Muchmore et al. 2008; Papadatos et al. 2010), we discuss
only the similarities themselves.
In a similar vein, the different encodings produce quite
different assessments of the number of metabolites to
Fig. 1 continued
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Fig. 2 Different structural
encodings produce different
drug-metabolite distances.
a Cumulative plots of nearest
drug-metabolite Tanimoto
distances using various
fingerprints. The number of
drugs with a Tanimoto
similarity of 0.5 or smaller is
arrowed (i.e. all of those to the
right, ca 90 %) have a Tanimoto
similarity greater than 0.5.
b Scatter plots relating the
nearest Tanimoto distance to a
metabolite for each drug; when
the closest metabolites are the
same for both encodings they
are coloured red. Correlation
coefficients are as given. The
blue histograms represent the
distributions of Tanimoto
similarities for each of the
encodings (scaled to fit the
relevant windows).
c Cumulative numbers of
metabolites with a Tanimoto
similarity C0.5 for various
drugs and encodings. d The
variation of the numbers of
metabolites with a Tanimoto
similarity C0.5 for all drugs
using the MACCS encoding,
with some of the highest
labelled by name and with the
chemical structure of arbekacin,
the ‘most promiscuously
metabolite-like’ of all, shown.
e The 14 least metabolite-like
drugs when using the MACCS
encoding. f An assessment of
part of drug-metabolite space
where drugs are largely but not
entirely distant from metabolites
(Color figure online)
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Fig. 2 continued
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Fig. 2 continued
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which each drug displays a Tanimoto similarity exceeding
0.5 (Fig. 2c), with (unsurprisingly, given the data in
Fig. 2a) the MACCS, RDKit and Layered encodings
showing the greatest tendency towards ‘metabolite-like-
ness’. Based on MACCS, 50 % of marketed drugs have at
least 31 metabolites with a TS of 0.5 or more. The ‘winner’
(i.e. the drug with the most metabolites to which it bears a
TS greater than or equal to 0.5) is arbekacin, with 364, and
the relevant data, plus a few named drugs, are given in
Fig. 2d. It is probably worth commenting, albeit this is not
necessarily a surprising finding, that these ‘highly metab-
olite-like’ drugs are natural products or molecules derived
therefrom [see also (Kell 2013; Newman and Cragg 2012)].
The average greatest TS to a metabolite of the five most
drug-like drugs (0.547), the five least drug-like drugs
(0.683), the five most drug-like Ro5 failures (0.496) and
the five least drug-like Ro5 passes (0.557, but minus te-
gaserod, not present in our list) as listed by Bickerton et al.
(2012) are as noted.
By contrast, the substance with the lowest NMTS
(perflutren, 0.125) is in fact an injectable contrast agent of
lipid microspheres marketed precisely because it does not
enter cells, while the next three lowest (NTS B 0.2) are
halothane (an inhalational narcotic), lindane (a topical
chlorinated insecticide) and desflurane (a polyfluorinated
inhalational anaesthetic), consistent with the fact that vir-
tually no natural human metabolites are halogenated. Ten
of the 14 least metabolite-like drugs contain at least two
halogens (Fig. 2e).
In a similar vein, it is possible to enquire as to which
metabolites have the most or fewest marketed drugs closely
associated with them in terms of Tanimoto similarity, the
latter in particular as a possible indication of areas of
chemical space that might be deemed to be relatively un-
derexplored. The metabolites with the very lowest TS to
drugs are small and uninteresting (ammonia, water, etc.),
so Fig. 2f illustrates those metabolites that are least similar
to numbers of drugs between 900 and 1,000, at the same
time illustrating the nonlinearity of drug and metabolite
spaces by encoding with colours those metabolites that
nonetheless have 1–5 drugs with a TS greater than or equal
to 0.9 (glycerol is marked and has one, viz. mannitol). One
might consider the sparsely populated areas of ‘metabolite-
likeness space’ to be ones worth pursuing in drug
discovery.
Another means of displaying the data, and a convenient
means of interrogating them for a drug of interest, is given
in Fig. 3, where we display the Tanimoto similarity to all
metabolites for the beta-(adrenergic receptor) blocker
propranolol. All metabolites with a TS greater than 0.5 are
labelled, and structures are shown for (from left to right)
propranolol itself, (-)-salsoline, adrenaline, L-normeta-
nephrine, metanephrine and norepinephrine. While
‘structural similarity’ may be seen as a subjective matter, in
this case the chemical similarities are obvious, and it is
probably not surprising that a beta-adrenergic antagonist
should have similarities of this type.
3.2 Multiobjective clustering of drugs and metabolites
In the above, we clustered (or bi-clustered) the drugs and
the metabolites separately. Another approach to assessing
the mapping of drug and metabolite spaces, and the extent
to which they overlap or otherwise), is to use clustering
methods of both together. These algorithms differ widely
[there is no single ‘correct’ clustering (Everitt 1993)] but
the state of the art is represented by methods such as
MOCK (Handl and Knowles 2007) (MultiObjective Clus-
tering with automatic K) that use multiple objectives
[specifically both closeness and connectivity (Handl and
Knowles 2007; Handl et al. 2005)] simultaneously to
cluster objects on the basis of their ‘similarity’. As with
any multiobjective method, there are multiple ‘best’ solu-
tions represented by a Pareto front (Kell 2012), and we
illustrate this in Fig. 4. Figure 4a shows the overall varia-
tion of ‘optimal’ cluster number for the Pareto front, with
‘knees’ at e.g. 3, 7, 25, 30, 42 and 64 clusters, while Fig. 4b
shows the distribution of drugs and metabolites in the
MOCK solution for 25 clusters. Also marked are the ‘top
ten’ blockbuster drugs by sales from 2010 [NB fluticasone
propionate and salmeterol are part of a combined medicine;
see also (Kell et al. 2013)], while the colour encodes the
cluster membership of compounds when there are only
seven clusters. Cluster 0 is mainly small metabolites like
bicarbonate, but it is evident that the lower clusters all
contain both metabolites and drugs. We also looked at the
distribution of various molecular properties (such as polar
surface area, molecular mass, log P etc.) between clusters,
but no trends nor hotspots were apparent for particular
clusters (not shown).
3.3 The drug-likeness of synthetic ‘druglike’ molecules
and ‘fragments’ and of natural products
Having seen the closeness of successful, marketed drugs to
metabolites when both are MACCS-encoded, it was
important to establish that (while unlikely) this was not a
strange artefact of the MACCS encoding itself. To this end,
and while we and others (e.g. Dobson et al. 2009; Feher
and Schmidt 2003; Khanna and Ranganathan 2011; Med-
ina-Franco and Maggiora 2014; Ohno et al. 2010) have
recognised that marketed drugs do differ structurally from
most molecules in drug discovery libraries, despite their
‘biogenic bias’ (Hert et al. 2009), we sought to see how
similar such non-marketed drug molecules or compounds
are to marketed drugs when we compare them in the same
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way. The comparison is not entirely favourable to metab-
olites since we already know (Fig. 2) that many of the very
smallest metabolite molecules are simply not druglike, and
this is reflected in the data of Fig. 5. Figure 5a shows a heat
map relating 2,000 structures taken randomly from the
30,000 in the Maybridge fragment library (similar kinds of
map were obtained using subsets of varying sizes up to
15,000) relative to marketed drugs, while Fig. 5b shows
that of a random subset of the Maybridge library vs Recon2
metabolites. Figure 5c shows the cumulative similarities
(all using MACCS encodings) to metabolites for a collec-
tion of molecules from a subset of 1,000 molecules from
the Maybridge fragment library, from the 13,533 com-
pounds in the Tres Cantos Antimalarial Drug Set (Gamo
Table 1 Summary of the most frequently represented ‘closest metabolite’ to FDA-approved drugs, the number of times they appear, and the
number of metabolites that are closest to a drug at least once






that are ‘closest’ to a
marketed drug at least once
MACCS Docosa-4,7,10,13,16-pentaenoic acid 52 359
Atom pair Linoleic coenzyme A 68 346
Feats Morgan Docosa-4,7,10,13,16-pentaenoic acid 124 319
Morgan Docosa-4,7,10,13,16-pentaenoic acid 77 338
RDKit Methylcobalamin 650 268
Layered Adenosylcobalamin 87 300
Avalon Cortisol 65 213
Torsion Vaccenyl coenzyme A 44 327
Fig. 3 Variation of the Tanimoto similarity for a marketed drug, propranolol, with various metabolites, those with a TS of over 0.5 being
labelled, and structures given for a representative set to illustrate the close chemical similarity (Color figure online)
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Fig. 4 Drug-metabolite clustering using the MACCS encoding and
MOCK, a multiobjective clustering algorithm. a Dependence of
cluster numbers as the weightings of the two main objectives are
varied. The ‘knees’ at cluster numbers of 2, 3, 7, 25, 30 and 64 are
marked. b Cluster membership and its distribution between drugs and
metabolites for when 25 clusters are chosen. Data are ‘jittered’ in the
Y direction to make them clearer (Color figure online)
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Fig. 5 Properties of drugs and
drug fragments. a Heat map
illustrating marketed drug-
compound distances of 2,000
drug fragments selected
randomly from a Maybridge
library (the plot looks very
similar for 15,000 fragments).
b Heat map illustrating
metabolite-compound distances
of 2,000 drug fragments
selected randomly from a
Maybridge library (the plot
looks very similar for 15,000
fragments). c Cumulative plots
of nearest marketed drug-
compound or marketed drug–
fragment Tanimoto distances
for various libraries.
d Distribution of molecular
weights for the various datasets
used (Color figure online)
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Fig. 5 continued
A ‘rule of 0.5’ for use in drug discovery 335
123
et al. 2010), from the 5,697 compounds in the Novartis
antimalarial collection (Guiguemde et al. 2010) (note that
these last two are in fact ‘hits’ or actives), for 3 subsets of
1,000 molecules from ZINC (Irwin et al. 2012), and of
1,000 from the *2,400 natural products molecules in
StreptomedB (Lucas et al. 2013). We also checked to
ensure that we are not biased systematically towards an
appearance of metabolite-likeness by say differences in
distributions of molecular weights in the different sets, and
Fig. 5d shows that we are not, in that a propensity to
metabolite-likeness does not seem to follow systematically
the MW distribution of the libraries. It is interesting to note
that the Novartis and GSK compounds, selected from a
very much larger set on the basis of their bioactivity, were
even slightly more ‘drug-like’ than were those from Recon
2 at the left-hand end, though Recon 2 was most drug-like
overall (note how it and the streptomycete secondary
metabolites ‘pull away’ from the other curves beyond
50 %, Fig. 5c), and it seems that no such ‘MACCS arte-
fact’ contributes to the ‘rule of 0.5’. Interestingly, May-
bridge tends to contain a rather greater diversity of
structures relative to human metabolites, but it is possible
that the libraries might be enriched further for possible
drugs if they were to include a greater degree of metabo-
lite-likeness. It will obviously be of future interest to
determine which fragments or compounds are enriched in
molecules that happen to possess particular bioactivities.
4 Discussion and conclusions
While both drug and drug target spaces are evidently very
heterogeneous (e.g. Adams et al. 2009; Hopkins et al. 2014;
Medina-Franco and Maggiora 2014; Paolini et al. 2006),
and that is reflected in the analyses presented here, it is
highly desirable to be able to find properties that are well
represented in marketed (and hence effective and success-
ful) drugs. Given the complexity of drug space, finding a
simple mnemonic or rule that has utility is to be welcomed.
Indeed, the original ‘rule of 5’ paper states (Lipinski et al.
1997) ‘‘This analysis led to a simple mnemonic which we
called the ‘rule of 5’ because the cutoffs for each of the four
parameters were all close to 5 or a multiple of 5….The ‘rule
of 5’ states that: poor absorption or permeation are more
likely when: there are more than 5 H-bond donors
(expressed as the sum of OHs and NHs); The MWT is over
500; the Log P is over 5 (or M Log P is over 4.15); there are
more than 10 H-bond acceptors (expressed as the sum of Ns
and Os); compound classes that are substrates for biological
transporters are exceptions to the rule.’’ This famous ‘rule
of 5’ (Lipinski et al. 1997) has been highly influential in this
regard, but only about 50 % of orally administered new
chemical entities actually obey it (Overington et al. 2006;
Zhang and Wilkinson 2007) (and see Hopkins et al. 2014);
indeed half of recent ‘new chemical entities’ are natural
products (Newman and Cragg 2012), that do not obey the
Ro5 either. The (also very effective) ‘rule of three’ (Con-
greve et al. 2003) applies solely to leads and not drugs.
While improving drug effectiveness is probably best
addressed using combinations of molecules (e.g. Small
et al. 2011), we have shown that when encoded using the
public MDL MACCS keys, more than 90 % of individual
marketed drugs obey a ‘rule of 0.5’ mnemonic, elaborated
here, to the effect that a successful drug is likely to lie
within a Tanimoto distance of 0.5 of a known human
metabolite. While this does not mean, of course, that a
molecule obeying the rule is likely to become a marketed
drug for humans, it does mean that a molecule that fails to
obey the rule is statistically most unlikely to do so. We note
that this highlighting of the utility of ‘metabolite-likeness’
as a concept in drug discovery in systems pharmacology is
just a first step, as the availability of Recon2 for such
analyses open up many new avenues that we do not discuss
here. The present analysis has necessarily been retrospec-
tive, as we have applied it to existing and successful (i.e.
presently marketed) drugs. However, we consider that this
rule, and the concept of the utility of metabolite-likeness
more generally, may well have significant prospective value
in reversing a current trend in medicinal chemistry (Chen
et al. 2012; Walters et al. 2011) that runs in a direction
precisely opposite to that of metabolite-likeness.
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